Prescription of drugs: problems and ways of solving
Abstract
In the article considers the place and value of the long-acting injectable antipsychotics in schizophrenia, summarized the advantages and disadvantages as well as problems related to their prescribing. Described the algorithm for patient’s engagement in the process of treatment and the specific doctor’s actions when prescribing the drug.
About the Author
N. B. Lutova
St.-Peresburg V.M. Bekhterev Psychoneurological Research Institute
Russian Federation
Russian Federation
References
1. Лутова Н.Б. Пролонгированные формы антипсихотиков в повседневной клинической практике (результаты опроса больных) // Журнал неврологии и психиатрии им. С.С. Корсакова. 2014. - № 10. - С. 65-68.
2. Морозова М.А. Палиперидона пальмитат - возможности терапии обострений у больных шизофренией пролонгированными атипичными антипсихотиками // Журнал неврологии и психиатрии. - 2012. - № 2. - С. 85 -88.
3. Мосолов С.Н., Калинин В.В. Еремин А.В. Сравнительная эффективность и переносимость нового поколения антипсихотических средств при лечении обострений шизофрении (метаанализ оригинальных исследований оланзапина, рисперидона, кветиапина, клозапина и галоперидола) // Новые достижения в терапии психических заболеваний/ Под ред. С.Н. Мосолова. - М. - 2002. - С. 82-94.
4. Незнанов Н.Г., Иванов М.В. Роль пролонгированных лекарственных форм в улучшении клинической картины и социальной адаптации пациентов с диагнозом шизофрении// Психиатрия и психофармакотерапия. - 2012 - Т. 14. - № 3. - С. 2-7.
5. Шрайнер А., Аадамсу К., Альматура А.С., и др. Рандомизированное двухлетнее со слепой оценкой исследование палиперидона пальмитата в сравнении с монотерапией выбранным исследователями пероральным антипсихотиком у больных шизофренией (PROSIPAL) расширенный реферат // Современная терапия психических расстройств. - 2016. - № 2. - С. 9-16.
6. Янушко М.Г., Либин Л.Я. Практические рекомендации по применению палиперидона пальмитата в лечении шизофрении. - М.: МЕДпресс-информ. - 2015. - 32с.
7. Altamura A., Sassella F., et al. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice // Drugs. - 2003. - Vol. 63. - P. 493-512.
8. Argo T.R., Crimson M.L., Miller A.L., et al. The Texas Medication Algorthm Project antipsychotic algorithm for schizophrenia. The Texas Department of State Health Services. - 2007.
9. Bai Y., Chen T., et al. A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-weeks randomized, single-blind study // Pharmacopsychiatry. - 2006. - Vol. 39(4). - P. 135-141.
10. Barrio P., Batalla A., Castellve P., et al. Effectiveness of long-acting injectable risperidine versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study. - Int Clinical Psychopharmacology. - 2013. - Vol. 28. - P. 164-170.
11. Berwaerts J., Liu Y., Gopal S., Nuamah I., et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia. A randomized clinical trial. - JAMA Psychiatry. - 2015. - Vol. 72. - P. 830-839.
12. Boca R., FlaWalburn J., Gray R., et al. Systematic review of patient and nurse attitudes to depot natipsychotics medication // Br J Psychiatry. - 2001. - Vol. 179. - P. 300-307.
13. Care Quality Commission. Mental health services: the 2008 survey of community mental health services. CQC 2009 (http://www.cgc.org.uk/usingcare-services/healthcare/patient-servey/mentalhealthservices.cfm
14. Coppola D., Liu Y., Gopal S., Remmerie B., et al. One-year prospective study of the safety, tolerability and pharmacokinetics of the heist available dose of paliperidone palmitate in patients with schizophrenia. - BMS Psychiatry. - 2012. - Vol. 12. - P. 26.
15. Emsley R. Il costo reale della non aderenza nella schizophrenia. - Mind Brain. - 2010. - Vol. 1. - P. 17-20.
16. Falfai P. Wodbrock T., Lieberman J., et al. World Federation Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophrenia. - World J Biolog Psychiatry. - 2005. - Vol. 6. - P. 132-191.
17. Greenson R.R. The working alliance and the transference neurosis // Psychoanal. Q. - 1965. - Vol. 34. - P. 155-181.
18. Hamann J., Koble J., Cohen R., et al. How do Psychiatrists choose among different antipsychotics? Eur J Clin Psychiatry. - 2005. - Vol. 61. - P. 851-854.
19. Heres S., Schmitz F.S., Leucht S., et al. The attitude of patients towards antipsychotic depotreatment. - Int Clin Psychopharmacol. - 2007. - Vol. 22. - P. 275-282.
20. Heres S., Lambert M., Vauth R., Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics. - European Psychiatry. - 2014. - Vol. 29. - P. 1409-1413.
21. Iyer S., Banks N., Roy M.A., et al. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part 1 -Physicians perspective. - Can J Psychiatry. - 2013. - Vol. 58. - P. 23-29.
22. Jaeger M., Rossler W. Attitudes towards long-acting depot anyipsychotics: A survey patients, relatives and nurses // Psychiarty Res. - 2010. - Vol. 175 (Issue 1-2). - P. 58-62.
23. Jeong H.G., Lee M.S. Long-acting injectable antipsychotics in first-episode schizophrenia. - Clinical Psychopharmacological and Neuroscience. - 2013. - Vol. 11. - P. 1-6.
24. Linden M., Pyrkosch L., Dittmann RW., Czekalla J., Why do physicians switch from one antipsychotic agent to another? The “physician drug stereotype”. - J Clin Psychopharmacology. - 2006. - Vol. 26. - P. 225-231.
25. Luborsky L. Helping alliance in psychotherapy // Successful Psychotherapy / ed. by J. L. Claghorn. - New York, NY: Brunner / Mazel Inc. - 1976. - P. 92-116.
26. Nasrallah H.A, Targum S.D., Tandon R., et al. Defining and measuring clinical effectiveness in the treatment of schizoprenia // Psychiatr Serv. - 2005. - Vol. 56. - P. 273-282.
27. Patel M.X., Haddad R.M., Chaudry I.B., et al. Psychiatrists’ use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years // J Psychopharmac. - 2010. - Vol. 24. - P. 1473-1482.
28. Patel M.X., Nikolaou V., David A.S. Psychiatrists’ attitudes to maintenance medication for patients with schizophrenia. Psychol Med 2003; 33: 83-89.
29. Potkin S., Bera R., Zubek D., Lau G. Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics an analysis of in-office discussion regarding LAI for schizophrenia // BMC Psychiatry. - 2013. - Vol. 13. - P. 261.
30. Schooler N.R. Relapse and rehospitalization: comparing oral and depot antipsychotics // J Clin Psychiatry. - 2003. - Vol. 64. - P. 14-17.
31. Stevens G.L., Dawson G., Zummo J. Clinical benefits and impact of early use of long-acting injectible antipsychotics for schizophrenia. Early Intervention in Psychiatry. - 2015. - №. 1. - P. 1-13.
32. Viala A., Cornic F., Vacheron MN. Treatment adherence with early prescription of long-acting injectable antipsychotics in recent-onset schizophrenia. - Schizophernia Res and Treatment. - 2012. - P. 1-5.
33. Waddell L., Taylor M. Attitudes of patients and mental health staff to antipsychotic long acting injections: systematic review. - Br J Psychiatry. - 2009. - Vol. 195. - P. 43-50.
34. Zetzel E.R. Current concepts of transference / E.R. Zetzel // Int. J. Psychoanal. - 1956. - Vol. 37. - P. 369-376.
Review
For citations:
Lutova N.B. Prescription of drugs: problems and ways of solving. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. 2017;(2):87-90. (In Russ.)
Views:
461
Email this article 